A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology
Authors:
Preprint
Abstract
Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. Here, we present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC . OA-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo . To measure the effect of OA-SPARC on neural firing in a scalable format for drug discovery, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell resolution and a throughput of up to 500,000 neurons per day, with patch clamp-like single action potential resolution. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology with different mechanisms of action. We screened ~3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of both functional OA-SPARC phenotype rescue and orthogonal “off-target” effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including well-known ion channel modulators as well as less characterized mechanisms including MEK inhibitors and tyrosine kinase modulators, providing validation of the platform for pain drug discovery.Keywords
All Related Versions
- Published version: Pain, 165 (4), 922.
This publication has 105 references indexed in Scilit:
- HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic painPain, 2013
- Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trialJournal of Translational Medicine, 2013
- The Effect of Bradykinin B2 Receptor Polymorphisms on the Susceptibility and Severity of Osteoarthritis in a Chinese CohortJournal of Biomedicine and Biotechnology, 2012
- Selective inhibition of extracellular signal-regulated kinases 1/2 blocks nerve growth factor to brain-derived neurotrophic factor signaling and suppresses the development of and reverses already established pain behavior in ratsNeuroscience, 2012
- The discovery and development of analgesics: new mechanisms, new modalitiesJournal of Clinical Investigation, 2010
- Cellular and Molecular Mechanisms of PainCell, 2009
- Automated Analysis of Cellular Signals from Large-Scale Calcium Imaging DataNeuron, 2009
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Monocyte chemoattractant protein‐1 functions as a neuromodulator in dorsal root ganglia neuronsJournal of Neurochemistry, 2007
- Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalinProceedings of the National Academy of Sciences, 2006